Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma

REFERENCES

• Amato , R. J. , Misellati , A. , Khan , M. , Chiang , S. ( 2006 ). A Phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC) . Journal of Clinical Oncology 24 ( 18 suppl ): abstract 4530 .
   PubMed Web of Science ®Google Scholar
• Atkins , M. B. , Hidalgo , M. , et al. ( 2004 ). Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma . Journal of Clinical Oncology 22 : 909 – 918 .
   PubMed Web of Science ®Google Scholar
• Cain , L. E. , Cole , S. R. ( 2009 ). Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death . Statistics in Medicine 28 : 1725 – 1738 .
   PubMed Web of Science ®Google Scholar
• Cole , S. R. , Chu , H. ( 2005 ). Effect of acyclovir on herpetic ocular recurrence using a structural nested model . Contemporary Clinical Trials 26 : 300 – 310 .
   PubMed Web of Science ®Google Scholar
• EMA/CHMP/205/95/rev.4 ( 2010 ). Guideline on the evaluation of anticancer medicinal products in man. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/12/WC500119966.pdf
   Google Scholar
• Demetri , G. D. , Huang , X. , et al. ( 2008 ). Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure . Journal of Clinical Oncology 26 ( May 20 suppl.): abstr. 10524 .
   Web of Science ®Google Scholar
• FDA Will Revisit Appropriate Use Of PFS Endpoints at Advisory Committee . ( 2009 ). Health News Daily , September .
   Google Scholar
• Fleming , T. , Harrington , D. ( 1981 ). A class of hypothesis tests for one and two samples of censored survival data . Communications in Statisitics 10 : 763 – 794 .
   Web of Science ®Google Scholar
• Fleming , T. R. , Rothmann , M. D. , Hong , L. L. (2009). Issues in using progression-free survival when evaluating oncology products. Journal of Clinical Oncology 27:2874–2880.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration . ( 2007 ). Guidance for Industry. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics . Washington , DC : U.S. Department of Health and Human Services .
   Google Scholar
• Hernán , M. A. , Cole , S. R. , Margolick , J. , Cohen , M. , Robins , J. M. ( 2005 ). Structural accelerated failure time models for survival analysis in studies with time-varying treatments . Pharmacoepidemiol Drug Safety 14 : 477 – 491 .
   PubMed Web of Science ®Google Scholar
• Holland , P. ( 1986 ). Statistics and causal inference . Journal of the American Statistical Association 81 : 945 – 961 .
   Web of Science ®Google Scholar
• Korhonen , P. , Laird , N. , Palmgren , J. ( 1999 ). Correcting for non-compliance in randomised trials: An application to the ATBC study . Statistics in Medicine 18 : 2879 – 2897 .
   PubMed Web of Science ®Google Scholar
• Motzer , R. J. , Escudier , B. , et al. ( 2008 ). Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled Phase III trial . Lancet 372 : 449 – 456 .
   PubMed Web of Science ®Google Scholar
• Motzer , R. , Escudier , B. , et al. ( 2010 ). Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors . Cancer 116 : 4256 – 4265 .
   PubMed Web of Science ®Google Scholar
• Robins , J. M. ( 1998a ). Structural nested failure time models . In: Andersen , P. K. , Keiding , N. , section eds. Survival Analysis. In: Armitage, P., Colton, C., eds . The Encyclopedia of Biostatistics . Chichester , UK : John Wiley and Sons , pp. 4372 – 4389 .
   Google Scholar
• Robins , J. M. ( 1998b ). Marginal structural models. In: 1997 Proceedings of the Section on Bayesian Statistical Science. Alexandria, VA: American Statistical Association, pp. 1–10 .
   Google Scholar
• Robins , J. M. ( 1999 ). Marginal structural models versus structural nested models as tools for causal inference . In: Halloran , E. , Berry , D. , eds. Statistical Models in Epidemiology: The Environment and Clinical Trials . New York , NY : Springer-Verlag , pp. 95 – 134 .
   Google Scholar
• Robins , J. M. , Hernán , M. A. , Brumback , B. ( 2000 ). Marginal structural models and causal inference in epidemiology . Epidemiology 11 : 550 – 560 .
   PubMed Web of Science ®Google Scholar
• Robins , J. M. , Tsiatis , A. A. ( 1991 ). Correcting for non-compliance in randomized trials using rank preserving structural failuretime models . Communications in Statistics 20 : 2609 – 2631 .
   Google Scholar
• Rubin , D. B. ( 1978 ). Bayesian inference for causal effects: The role of randomization . Annals of Statistics 6 : 34 – 58 .
   Web of Science ®Google Scholar
• White , I. R. , Babiker , A. G. , Walker , S. , Darbyshire , J. H. ( 1999 ). Randomization-based methods for correcting for treatment changes: Examples from the Concorde trial . Statistics in Medicine 18 : 2617 – 2634 .
   PubMed Web of Science ®Google Scholar